We could see substantial movement to the upside before "late 2013". There is alot going on behind the scenes. If the phase I AMR-102 trial is successful alot of questions will have to be answered. Will the FDA allow Amarin to skip Phase II trials and move right into Phase III trials? If so does Amarin have the cash to pursue this alone? I'm sure Phizer would love to be involved in AMR-102. Then we have the patent info on the metabolite of Avorstatin...etc.
Lots of issues in the air. Should be coming to a head soon.
News 
Market Data 
Discover 
AI
